Turgut KARABAĞ, Kenan DEMİR, Coşkun KAYA, Mehmet TOKAÇ, Sadık BÜYÜKBAŞ, Fatih KOÇ, Volkan KOCABAŞ, Sami ERDEM, Yusuf ALİHANOĞLU, Ahmet KAYA

Ghrelin, resistin and leptin levels in patients with metabolic syndrome

Amaç: Bu çalışmada metabolik sendromlu (MS) hastalar ile sağlıklı kontroller arasında açlık ghrelin, leptin ve resistin düzeylerinin karşılaştırılması amaçlanmıştır. Metod: Çalışmaya 21 MS hastası (7 erkek; ortalama yaş, 44±4) ve 17 sağlıklı kontrol (8 erkek; ortalama yaş 43±3) alınmıştır. MS tanısı Ulusal Kolesterol Eğitim Programı (NCEP) Erişkin Tedavi Paneli (ATP) III kriterlerine göre tanımlandı. MS karşılama kriterlerinden en az 3’üne sahip olan ve beden kitle indeksi (BKI) ≥30 kg/m² olan hastalar MS grubuna seçildi. Sağlıklı gönüllüler arasında BKI

Metabolik sendromlu hastalarda grelin, rezistin ve leptin düzeyleri

Aim: This study was designed to compare the fasting ghrelin, leptin and resistin levels between metabolic syndrome (MS) patients with healthy controls. Method: This trial was performed on 21 patients with MS (7 men; mean age, 44±4 years) and 17 healthy controls (8 men; mean age, 43±3 years). Diagnosis of MS was defined based on National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III criteria. Patients meeting at least 3 of the MS criteria, with a body mass index (BMI) ≥30 kg/m² were included in the MS group. Among healthy volunteers, those with a BMI

PDF

___

1. Rabe K, Lehrke M, Parhofer KG, et al. Adipokines and insulin resistance. Mol Med 2008;14:741-51.
2. Hamdy O, Ledbury S, Mullooly C, et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 2003;26:2119-25.
3. Ukkola O and Bouchard C. Clustering of metabolic abnormalities in obese individuals: the role of genetic factors. Ann Med 2001;33:79-90.
4. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999;892:146-54.
5. Kojima M and Kangawa K. Ghrelin: structure and function. Physiol Rev 2005;85:495-22.
6. Luis DA, Aller R, Izaola O, et al. Influence of insulin resistance and adipocytokines on elevated serum alanine aminotransferase in obese patients. Arch Med Res 2008;39:110-14.
7. Ukkola O, Pöykkö SM, Antero Kesäniemi Y. Low plasma ghrelin concentration is an indicator of the metabolic syndrome. Ann Med 2006;38:274-79.
8. Nogueiras R, Tschöp MH, Zigman JM. Central nervous system regulation of energy metabolism: ghrelin versus leptin. Ann N Y Acad Sci 2008;1126:14-9.
9. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992-95.
10. Ukkola O, Poykko S, Paivansalo M, et al. Interactions between ghrelin, leptin and IGF-I affect metabolic syndrome and early atherosclerosis. Ann Med 2008;29:1-9.
11. Savino F, Liguori SA. Update on breast milk hormones: leptin, ghrelin and adiponectin. Clin Nutr 2008;27:42-7.
12. Schur EA, Cummings DE, Callahan HS, et al. Association of cognitive restraint with ghrelin, leptin, and insulin levels in subjects who are not weight-reduced. Physiol Behav 2008;93:706-12.
13. Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001;50:227-32.
14. Chu S, Ding W, Li K, et al. Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circ J 2008;72:1249-53.
15. Savage DB, Sewter CP, Klenk ES, et al. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator- activated receptor-gamma action in humans. Diabetes 2001;50:2199-202.
16. Bideci A, Camurdan MO, Yeşilkaya E, et al. Serum ghrelin, leptin and resistin levels in adolescent girls with polycystic ovary syndrome. J Obstet Gynaecol Res 2008;34:578- 84.
17. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
18. Yingzhong Y, Droma Y, Rili G, et al. Regulation of body weight by leptin, with special reference to hypoxia-induced regulation. Intern Med 2006;45:941-46.
19. Yoshinaga M, Sameshima K, Tanaka Y. Adipokines and the prediction of the accumulation of cardiovascular risk factors or the presence of metabolic syndrome in elementary school children. Circ J 2008;72:1874-78.
20. Daghestani MH, Ozand PT, Al-Himadi AR, et al. Hormonal levels of leptin, insulin, ghrelin, and neuropeptide Y in lean, overweight, and obese Saudi females. Saudi Medical Journal 2007;28:1191-97.
21. Tschop M, Weyer C, Tatarannı PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001;50:707-09.
22. Park HS, Lee KU, Kim YS, et al. Relationships between fasting plasma ghrelin levels and metabolic parameters in children and adolescents. Metabolism 2005;54:925-29.
23. Monti V, Carlson JJ, Hunt SC, et al. Relationship of ghrelin and leptin hormones with body mass index and waist circumference in a random sample of adults. J Am Diet Assoc 2006;106:822-28.
24. Ikezaki A, Hosoda H, Ito K et al. Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents. Diabetes 2002;51:3408-11.
25. Verma S, Li SH, Wang CH et al. Resistin promotes endothelial cell activation: Further evidence of adipokine-endothelial interaction. Circulation 2003;108:736-40.
26. Reilly MP, Lehrke M, Wolfe ML, et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005;111:932-39.